We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Potential Shortcoming of Antibiotic Lab Tests Determined

By LabMedica International staff writers
Posted on 18 Jul 2018
As multidrug-resistant organisms continue to emerge, specific tests, called antibiotic susceptibility assays, are increasingly critical. More...
Clinicians depend on reliable results when choosing the right drug to treat patients.

To determine which antibiotics reliably treat which bacterial infections, diagnostic laboratories that focus on clinical microbiology test pathogens isolated from patients for antibiotic sensitivity. However, a recent study reveals that one aspect of these tests may fall short and not be stringent enough.

Microbiologists at the Beth Israel Deaconess Medical Center (Boston MA, USA) and their colleagues examined pathogens cited by the US Centers for Disease Control and Prevention (Atlanta GA, USA) and the World Health Organization (Geneva, Switzerland) as urgent and concerning drug resistance threats.

To obtain consistently reliable results, scientists conducting antibiotic susceptibility assays follow national guidelines with standardized methods, including the use of a specific number of organisms, or "inoculum" that is added to each assay. There is a target inoculum, and then a range of an allowable inoculum, or acceptable upper and lower bounds around the target inoculum.

The team found that the susceptibility determination against two broad spectrum drugs, meropenem and cefepime, were dramatically affected by inoculum differences within the allowable range of inoculum. Although they have no idea about how often clinical laboratories deviate even beyond the allowable range, they expect this happens with some frequency and would further skew results. The findings indicate that clinical microbiology laboratories must hit the target inoculum as accurately as possible to obtain reliable testing results for multidrug-resistant pathogens.

James Kirby, MD, the Director of the Clinical Microbiology Laboratory and senior co-author, said, “Our question was whether this wiggle room impacts results. Our findings were clear: inoculum matters.” The study was published on May 21, 2018, in the journal Antimicrobial Agents and Chemotherapy.

Related Links:
Beth Israel Deaconess Medical Center
US Centers for Disease Control and Prevention
World Health Organization


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Portable POCT Blood Gas Analyzer
BD100
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.